Advertisement

Tumour infiltrating lymphocytes and correlation with response to intensified platinum-based chemotherapy in BRCA-like tumours

Published:January 20, 2020DOI:https://doi.org/10.1016/j.ejca.2019.12.004
      Tumour-infiltrating lymphocytes (TILs) are an emerging biomarker in breast cancer (BC) [
      • Savas P.
      • Salgado R.
      • Denkert C.
      • Sotiriou C.
      • Darcy P.K.
      • Smyth M.J.
      • et al.
      Clinical relevance of host immunity in breast cancer: from TILs to the clinic.
      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Savas P.
        • Salgado R.
        • Denkert C.
        • Sotiriou C.
        • Darcy P.K.
        • Smyth M.J.
        • et al.
        Clinical relevance of host immunity in breast cancer: from TILs to the clinic.
        Nat Rev Clin Oncol. 2016; 13: 228-241
        • Loi S.
        • Sirtaine N.
        • Piette F.
        • Salgado R.
        • Viale G.
        • Van Eenoo F.
        • et al.
        Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: big 02-98.
        J Clin Oncol : official journal of the American Society of Clinical Oncology. 2013; 31: 860-867
        • Denkert C.
        • von Minckwitz G.
        • Darb-Esfahani S.
        • Lederer B.
        • Heppner B.I.
        • Weber K.E.
        • et al.
        Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
        Lancet Oncol. 2018; 19: 40-50
        • Adams S.
        • Gray R.J.
        • Demaria S.
        • Goldstein L.
        • Perez E.A.
        • Shulman L.N.
        • et al.
        Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.
        J Clin Oncol : official journal of the American Society of Clinical Oncology. 2014; 32: 2959-2966
        • Loi S.
        • Michiels S.
        • Salgado R.
        • Sirtaine N.
        • Jose V.
        • Fumagalli D.
        • et al.
        Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
        Ann Oncol : official journal of the European Society for Medical Oncology/ESMO. 2014; 25: 1544-1550
        • Salgado R.
        • Denkert C.
        • Campbell C.
        • Savas P.
        • Nuciforo P.
        • Aura C.
        • et al.
        Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial.
        JAMA oncology. 2015; 1: 448-454
        • Pruneri G.
        • Gray K.P.
        • Vingiani A.
        • Viale G.
        • Curigliano G.
        • Criscitiello C.
        • et al.
        Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
        Breast Canc Res Treat. 2016; 158: 323-331
        • Loi S.
        • Drubay D.
        • Adams S.
        • Pruneri G.
        • Francis P.A.
        • Lacroix-Triki M.
        • et al.
        Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient Analysis of early-stage triple-negative breast cancers.
        J Clin Oncol : official journal of the American Society of Clinical Oncology. 2019; 37: 559-569
        • Stanton S.E.
        • Adams S.
        • Disis M.L.
        Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review.
        JAMA oncology. 2016; 2: 1354-1360
        • Dieci M.V.
        • Radosevic-Robin N.
        • Fineberg S.
        • van den Eynden G.
        • Ternes N.
        • Penault-Llorca F.
        • et al.
        Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.
        Semin Cancer Biol. 2018; 52: 16-25
        • Park J.H.
        • Jonas S.F.
        • Bataillon G.
        • Criscitiello C.
        • Salgado R.
        • Loi S.
        • et al.
        Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy.
        Ann Oncol. 2019 Dec 1; 30: 1941-1949https://doi.org/10.1093/annonc/mdz395
        • Burstein H.J.
        • Curigliano G.
        • Loibl S.
        • Dubsky P.
        • Gnant M.
        • Poortmans P.
        • et al.
        Estimating the benefits of therapy for early stage breast cancer the St gallen international Consensus guidelines for the primary therapy of early breast cancer 2019.
        Annals of Oncol: Official J European Soci Med Oncol/ESMO. 2019;
        • Solinas C.
        • Marcoux D.
        • Garaud S.
        • Vitória J.R.
        • Van den Eynden G.
        • de Wind A.
        • et al.
        BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer.
        Cancer Lett. 2019; 450: 88-97
        • Lakhani S.R.
        • Jacquemier J.
        • Sloane J.P.
        • Gusterson B.A.
        • Anderson T.J.
        • van de Vijver M.J.
        • et al.
        Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.
        J Natl Cancer Inst. 1998; 90: 1138-1145
        • Sønderstrup I.M.H.
        • Jensen M.B.
        • Ejlertsen B.
        • Eriksen J.O.
        • Gerdes A.M.
        • Kruse T.A.
        • et al.
        Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
        Acta Oncol. 2019; 58: 363-370
        • Rodenhuis S.
        • Bontenbal M.
        • Beex L.V.
        • Wagstaff J.
        • Richel D.J.
        • Nooij M.A.
        • et al.
        High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.
        N Engl J Med. 2003; 349: 7-16
        • de Boo L.
        • Cimino-Mathews A.
        • Lubeck Y.
        • Daletzakis A.
        • Opdam M.
        • Sanders J.
        • et al.
        Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomized to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
        Eur J Cancer. 2020; 127: 240-250

      Linked Article